ARTEMIS
Live / Registered — Registered — Sections 8 & 15 accepted and acknowledged (as of 03 May 2025)
What this means for you
Registered since 29 Oct 2019. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 86880860
- Registration number
- 5897433
- Mark type
- Stylized text
- Filed
- 20 Jan 2016
- Published for opposition
- 15 Aug 2017
- Registered
- 29 Oct 2019
- Attorney of record
- Muzamil Huq
Goods and services
- Class 005 — Pharmaceuticals: Biologics, namely, chimeric immune cell antigen receptors, namely, engineered immune cells made from an individual patient's immune cells and proprietary DNA, for therapeutic use for the treatment of cancers, for the treatment of proliferative cell diseases [ , and in transplantation ]
Owner
- EUREKA THERAPEUTICS, INC., Emeryville, CA, US
- Eureka Therapeutics, Inc., Emeryville, CA, US
- Eureka Therapeutics, Inc., Emeryville, CA, US
- Eureka Therapeutics, Inc., Emeryville, CA, US
Prosecution history
- 03 May 2025 — NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
- 03 May 2025 — REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
- 03 May 2025 — CASE ASSIGNED TO POST REGISTRATION PARALEGAL
- 15 Jan 2025 — TEAS SECTION 8 & 15 RECEIVED
- 29 Oct 2024 — COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
- 29 Apr 2021 — AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
- 29 Oct 2019 — REGISTERED-PRINCIPAL REGISTER
- 24 Sept 2019 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 23 Sept 2019 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 21 Sept 2019 — STATEMENT OF USE PROCESSING COMPLETE
- 30 Aug 2019 — USE AMENDMENT FILED
- 21 Sept 2019 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 30 Aug 2019 — TEAS STATEMENT OF USE RECEIVED
- 28 Mar 2019 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 26 Mar 2019 — SOU EXTENSION 3 GRANTED